Australia Changes Patent Notification Requirements
Generic And Biosimilar Filers Must Notify Patent Holders Before TGA Evaluation
Australia’s Therapeutic Goods Administration has set out proposals for a change to early-notification requirements for generic and biosimilar sponsors.
You may also be interested in...
A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.
Dr Reddy’s says it has suffered a cyber-attack and has isolated “all data center services” so that it can take actions to mitigate the impact.